If you loved our Explainer on Cell and Gene Therapy, you'll love this new summarised version. This short report takes you through the key BIA member companies working in the AMR space, and explains the cutting-edge work taking place in the UK.
In this blog, Jaime Eaton, reflects on this month's Community Connects series, bringing together diverse expertise to tackle the most pressing challenges in our sector.
PrecisionLife and Ovation announce results of first phase to develop drug-response biomarkers to quantitively predict the efficacy, safety and tolerability of glucagon-like peptide-1 receptor agonist (GLP-1).
A multiple myeloma candidate with a new mode of action is now in Phase 2 patient trials following positive Phase 1 results showing it kills cancer cells without toxicity to patients.
